Oklahoma City, OKNCT07219420Now EnrollingIRB Ready

Palmoplantar Pustulosis Clinical Trial in Oklahoma City, OK

Access cutting-edge palmoplantar pustulosis treatment through this clinical trial at a research site in Oklahoma City. Study-provided care at no cost to qualified participants.

Sponsored by UCB Biopharma SRL

Quick Self-Assessment

See if you qualify for this Oklahoma City location

Preparing your pre-screening questions…

Expert Care in Oklahoma City

Access palmoplantar pustulosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related palmoplantar pustulosis treatment provided free

Apply for This Oklahoma City Location

Check if you qualify for this palmoplantar pustulosis clinical trial in Oklahoma City, OK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Oklahoma City

    Convenient for OK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Oklahoma City site if eligible
  4. 4Begin participation

About This Palmoplantar Pustulosis Study in Oklahoma City

The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).

Sponsor: UCB Biopharma SRL

Who Can Participate

Inclusion Criteria

At least 18 years of age inclusive, at the time of signing the informed consent form (ICF)
Have a palmoplantar pustulosis (PPP) diagnosis for at least 24 weeks prior to the Screening Visit
Have PPPASI ≥12 at the Screening Visit and Baseline Visit
Have PPP-IGA ≥3 at the Screening Visit and Baseline Visit
Have pustules on the palms of the hands and/or soles of the feet at the Screening Visit and Baseline Visit, defined as pustule severity ≥2 and having more than 5 active pustules
Participant must be a candidate for systemic therapy or phototherapy

Exclusion Criteria

Has PPP symptoms which improve significantly between the Screening Visit and Baseline Visit, defined as a reduction in the PPPASI score
Has the following: palmoplantar PSO (plaque PSO on palms/soles), guttate PSO, erythrodermic PSO (EP), generalized pustular PSO (GPP), Acrodermatitis continua of Hallopeau (ACH), atopic dermatitis, dyshidrotic eczema or chronic hand eczema.
Has drug-induced PSO (eg, first onset or current exacerbation due to beta blockers, calcium channel inhibitors, lithium, or tumor necrosis factor \[TNF\] inhibitor) or drug-induced pustular PSO (eg, acute generalized exanthematous pustulosis, acute localized exanthematous pustulosis)
Has cutaneous lesions that may interfere with the evaluation of the affected area and/or evaluation of the severity of PPP
Is taking or has taken prohibited or restricted medications without meeting the mandatory discontinuation or stability period relative to the Baseline Visit
Is taking or has ever taken an interleukin (IL)-17A/IL-17F inhibitor, including bimekizumab, or has participated in a bimekizumab investigational study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Oklahoma City?

Yes, this clinical trial (NCT07219420) has an active research site in Oklahoma City, OK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Palmoplantar Pustulosis Treatment Options in Oklahoma City, OK

If you're searching for palmoplantar pustulosis treatment options in Oklahoma City, OK, this clinical trial (NCT07219420) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Oklahoma City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced palmoplantar pustulosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Oklahoma City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Oklahoma City, OK